nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—breast cancer	0.78	1	CbGaD
Azilsartan medoxomil—Tasosartan—AGTR2—breast cancer	0.00245	0.292	CrCbGaD
Azilsartan medoxomil—Olmesartan—SLCO1B1—breast cancer	0.000896	0.107	CrCbGaD
Azilsartan medoxomil—Tasosartan—AGTR1—breast cancer	0.00085	0.101	CrCbGaD
Azilsartan medoxomil—Olmesartan—AGTR1—breast cancer	0.000718	0.0856	CrCbGaD
Azilsartan medoxomil—Telmisartan—AGTR1—breast cancer	0.000693	0.0826	CrCbGaD
Azilsartan medoxomil—AGTR1—nipple—breast cancer	0.000599	0.224	CbGeAlD
Azilsartan medoxomil—Candesartan—AGTR1—breast cancer	0.000559	0.0666	CrCbGaD
Azilsartan medoxomil—Muscle spasms—Goserelin—breast cancer	0.000485	0.00324	CcSEcCtD
Azilsartan medoxomil—Nausea—Fulvestrant—breast cancer	0.000485	0.00323	CcSEcCtD
Azilsartan medoxomil—Angioedema—Tamoxifen—breast cancer	0.000482	0.00322	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ixabepilone—breast cancer	0.00048	0.0032	CcSEcCtD
Azilsartan medoxomil—Nausea—Toremifene—breast cancer	0.000478	0.00319	CcSEcCtD
Azilsartan medoxomil—Pruritus—Ixabepilone—breast cancer	0.000473	0.00316	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Paclitaxel—breast cancer	0.000473	0.00315	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Vinorelbine—breast cancer	0.000471	0.00314	CcSEcCtD
Azilsartan medoxomil—Dizziness—Exemestane—breast cancer	0.000469	0.00313	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Methotrexate—breast cancer	0.000458	0.00305	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Ixabepilone—breast cancer	0.000458	0.00305	CcSEcCtD
Azilsartan medoxomil—Asthenia—Letrozole—breast cancer	0.000452	0.00302	CcSEcCtD
Azilsartan medoxomil—Asthenia—Anastrozole—breast cancer	0.000452	0.00302	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Thiotepa—breast cancer	0.00045	0.003	CcSEcCtD
Azilsartan medoxomil—Losartan—SLCO1B1—breast cancer	0.000449	0.0535	CrCbGaD
Azilsartan medoxomil—Rash—Exemestane—breast cancer	0.000447	0.00298	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Exemestane—breast cancer	0.000446	0.00298	CcSEcCtD
Azilsartan medoxomil—Pruritus—Letrozole—breast cancer	0.000445	0.00297	CcSEcCtD
Azilsartan medoxomil—Pruritus—Anastrozole—breast cancer	0.000445	0.00297	CcSEcCtD
Azilsartan medoxomil—Dizziness—Ixabepilone—breast cancer	0.000442	0.00295	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Melphalan—breast cancer	0.000437	0.00292	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Methotrexate—breast cancer	0.000432	0.00289	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Anastrozole—breast cancer	0.000431	0.00288	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Letrozole—breast cancer	0.000431	0.00288	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Epirubicin—breast cancer	0.000428	0.00286	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Goserelin—breast cancer	0.000426	0.00285	CcSEcCtD
Azilsartan medoxomil—Rash—Ixabepilone—breast cancer	0.000422	0.00281	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ixabepilone—breast cancer	0.000421	0.00281	CcSEcCtD
Azilsartan medoxomil—Nausea—Exemestane—breast cancer	0.000421	0.00281	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Irinotecan—breast cancer	0.00042	0.00281	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Chlorambucil—breast cancer	0.000418	0.00279	CcSEcCtD
Azilsartan medoxomil—Fatigue—Chlorambucil—breast cancer	0.000417	0.00279	CcSEcCtD
Azilsartan medoxomil—Dizziness—Letrozole—breast cancer	0.000416	0.00278	CcSEcCtD
Azilsartan medoxomil—Dizziness—Anastrozole—breast cancer	0.000416	0.00278	CcSEcCtD
Azilsartan medoxomil—Angioedema—Vinorelbine—breast cancer	0.000413	0.00275	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Gemcitabine—breast cancer	0.000411	0.00274	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Melphalan—breast cancer	0.00041	0.00274	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Gemcitabine—breast cancer	0.00041	0.00273	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Idarubicin—breast cancer	0.000409	0.00273	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Raloxifene—breast cancer	0.000409	0.00273	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Epirubicin—breast cancer	0.000405	0.0027	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Goserelin—breast cancer	0.000404	0.00269	CcSEcCtD
Azilsartan medoxomil—AGTR1—epithelium—breast cancer	0.000403	0.151	CbGeAlD
Azilsartan medoxomil—Skin disorder—Goserelin—breast cancer	0.0004	0.00267	CcSEcCtD
Azilsartan medoxomil—Nausea—Ixabepilone—breast cancer	0.000397	0.00265	CcSEcCtD
Azilsartan medoxomil—Rash—Letrozole—breast cancer	0.000397	0.00265	CcSEcCtD
Azilsartan medoxomil—Rash—Anastrozole—breast cancer	0.000397	0.00265	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Letrozole—breast cancer	0.000397	0.00265	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Anastrozole—breast cancer	0.000397	0.00265	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Doxorubicin—breast cancer	0.000396	0.00265	CcSEcCtD
Azilsartan medoxomil—Dizziness—Raloxifene—breast cancer	0.000395	0.00264	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Irinotecan—breast cancer	0.000388	0.00259	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Capecitabine—breast cancer	0.000388	0.00259	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—breast cancer	0.000382	0.00255	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Gemcitabine—breast cancer	0.000378	0.00252	CcSEcCtD
Azilsartan medoxomil—Rash—Idarubicin—breast cancer	0.000377	0.00252	CcSEcCtD
Azilsartan medoxomil—Rash—Raloxifene—breast cancer	0.000377	0.00252	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Idarubicin—breast cancer	0.000376	0.00251	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Raloxifene—breast cancer	0.000376	0.00251	CcSEcCtD
Azilsartan medoxomil—Telmisartan—ABCG2—breast cancer	0.000376	0.0448	CrCbGaD
Azilsartan medoxomil—Blood uric acid increased—Doxorubicin—breast cancer	0.000374	0.0025	CcSEcCtD
Azilsartan medoxomil—Nausea—Anastrozole—breast cancer	0.000374	0.0025	CcSEcCtD
Azilsartan medoxomil—Nausea—Letrozole—breast cancer	0.000374	0.0025	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Tamoxifen—breast cancer	0.000372	0.00248	CcSEcCtD
Azilsartan medoxomil—Fatigue—Tamoxifen—breast cancer	0.000371	0.00248	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—breast cancer	0.000365	0.00243	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Melphalan—breast cancer	0.000364	0.00243	CcSEcCtD
Azilsartan medoxomil—Fatigue—Melphalan—breast cancer	0.000364	0.00243	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Vinorelbine—breast cancer	0.000361	0.00241	CcSEcCtD
Azilsartan medoxomil—Losartan—AGTR1—breast cancer	0.00036	0.0429	CrCbGaD
Azilsartan medoxomil—Muscle spasms—Irinotecan—breast cancer	0.000358	0.00239	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Vinorelbine—breast cancer	0.000358	0.00239	CcSEcCtD
Azilsartan medoxomil—Nausea—Idarubicin—breast cancer	0.000355	0.00237	CcSEcCtD
Azilsartan medoxomil—Nausea—Raloxifene—breast cancer	0.000355	0.00237	CcSEcCtD
Azilsartan medoxomil—Fatigue—Goserelin—breast cancer	0.000355	0.00237	CcSEcCtD
Azilsartan medoxomil—Asthenia—Chlorambucil—breast cancer	0.000347	0.00232	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Thiotepa—breast cancer	0.000345	0.0023	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Paclitaxel—breast cancer	0.000344	0.00229	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Paclitaxel—breast cancer	0.000343	0.00229	CcSEcCtD
Azilsartan medoxomil—Pruritus—Chlorambucil—breast cancer	0.000342	0.00229	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Thiotepa—breast cancer	0.000342	0.00228	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Chlorambucil—breast cancer	0.000331	0.00221	CcSEcCtD
Azilsartan medoxomil—AGTR1—pituitary gland—breast cancer	0.000327	0.122	CbGeAlD
Azilsartan medoxomil—AGTR1—adipose tissue—breast cancer	0.000326	0.122	CbGeAlD
Azilsartan medoxomil—Asthenia—Vinblastine—breast cancer	0.000318	0.00212	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000318	0.00212	CcSEcCtD
Azilsartan medoxomil—Fatigue—Vinorelbine—breast cancer	0.000318	0.00212	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Paclitaxel—breast cancer	0.000317	0.00211	CcSEcCtD
Azilsartan medoxomil—Asthenia—Tamoxifen—breast cancer	0.000309	0.00206	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—breast cancer	0.000307	0.00205	CcSEcCtD
Azilsartan medoxomil—Pruritus—Tamoxifen—breast cancer	0.000305	0.00203	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Thiotepa—breast cancer	0.000304	0.00203	CcSEcCtD
Azilsartan medoxomil—Fatigue—Thiotepa—breast cancer	0.000303	0.00203	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Vinblastine—breast cancer	0.000303	0.00203	CcSEcCtD
Azilsartan medoxomil—Asthenia—Melphalan—breast cancer	0.000303	0.00202	CcSEcCtD
Azilsartan medoxomil—AGTR1—female reproductive system—breast cancer	0.000299	0.112	CbGeAlD
Azilsartan medoxomil—Pruritus—Melphalan—breast cancer	0.000299	0.00199	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Irinotecan—breast cancer	0.000298	0.00199	CcSEcCtD
Azilsartan medoxomil—Asthenia—Goserelin—breast cancer	0.000295	0.00197	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Mitoxantrone—breast cancer	0.000295	0.00197	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Tamoxifen—breast cancer	0.000295	0.00197	CcSEcCtD
Azilsartan medoxomil—Dizziness—Vinblastine—breast cancer	0.000293	0.00196	CcSEcCtD
Azilsartan medoxomil—AGTR1—adrenal gland—breast cancer	0.000292	0.109	CbGeAlD
Azilsartan medoxomil—Muscle spasms—Paclitaxel—breast cancer	0.000292	0.00195	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Docetaxel—breast cancer	0.000291	0.00195	CcSEcCtD
Azilsartan medoxomil—Pruritus—Goserelin—breast cancer	0.000291	0.00194	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Docetaxel—breast cancer	0.000291	0.00194	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Gemcitabine—breast cancer	0.00029	0.00194	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Melphalan—breast cancer	0.000289	0.00193	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Gemcitabine—breast cancer	0.000288	0.00192	CcSEcCtD
Azilsartan medoxomil—Nausea—Chlorambucil—breast cancer	0.000288	0.00192	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Fluorouracil—breast cancer	0.000286	0.00191	CcSEcCtD
Azilsartan medoxomil—Dizziness—Tamoxifen—breast cancer	0.000285	0.0019	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Capecitabine—breast cancer	0.000282	0.00188	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Goserelin—breast cancer	0.000282	0.00188	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Capecitabine—breast cancer	0.000281	0.00188	CcSEcCtD
Azilsartan medoxomil—Angioedema—Paclitaxel—breast cancer	0.000278	0.00185	CcSEcCtD
Azilsartan medoxomil—Dizziness—Goserelin—breast cancer	0.000272	0.00182	CcSEcCtD
Azilsartan medoxomil—Rash—Tamoxifen—breast cancer	0.000272	0.00181	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Tamoxifen—breast cancer	0.000271	0.00181	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Epirubicin—breast cancer	0.00027	0.0018	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Docetaxel—breast cancer	0.000268	0.00179	CcSEcCtD
Azilsartan medoxomil—Rash—Melphalan—breast cancer	0.000266	0.00178	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Melphalan—breast cancer	0.000266	0.00177	CcSEcCtD
Azilsartan medoxomil—Asthenia—Vinorelbine—breast cancer	0.000264	0.00177	CcSEcCtD
Azilsartan medoxomil—Nausea—Vinblastine—breast cancer	0.000263	0.00176	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Irinotecan—breast cancer	0.000262	0.00175	CcSEcCtD
Azilsartan medoxomil—Fatigue—Irinotecan—breast cancer	0.000262	0.00175	CcSEcCtD
Azilsartan medoxomil—Fatigue—Mitoxantrone—breast cancer	0.000262	0.00175	CcSEcCtD
Azilsartan medoxomil—Pruritus—Vinorelbine—breast cancer	0.000261	0.00174	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Capecitabine—breast cancer	0.00026	0.00173	CcSEcCtD
Azilsartan medoxomil—Candesartan—PTGS1—breast cancer	0.00026	0.0309	CrCbGaD
Azilsartan medoxomil—Rash—Goserelin—breast cancer	0.000259	0.00173	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Goserelin—breast cancer	0.000259	0.00173	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000257	0.00171	CcSEcCtD
Azilsartan medoxomil—Nausea—Tamoxifen—breast cancer	0.000256	0.00171	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000256	0.00171	CcSEcCtD
Azilsartan medoxomil—Fatigue—Gemcitabine—breast cancer	0.000255	0.0017	CcSEcCtD
Azilsartan medoxomil—AGTR1—endocrine gland—breast cancer	0.000253	0.0947	CbGeAlD
Azilsartan medoxomil—Asthenia—Thiotepa—breast cancer	0.000253	0.00169	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Vinorelbine—breast cancer	0.000252	0.00168	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000251	0.00168	CcSEcCtD
Azilsartan medoxomil—Nausea—Melphalan—breast cancer	0.000251	0.00167	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Doxorubicin—breast cancer	0.00025	0.00167	CcSEcCtD
Azilsartan medoxomil—Pruritus—Thiotepa—breast cancer	0.000249	0.00166	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Docetaxel—breast cancer	0.000248	0.00165	CcSEcCtD
Azilsartan medoxomil—Nausea—Goserelin—breast cancer	0.000244	0.00163	CcSEcCtD
Azilsartan medoxomil—Dizziness—Vinorelbine—breast cancer	0.000244	0.00163	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Paclitaxel—breast cancer	0.000243	0.00162	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Thiotepa—breast cancer	0.000241	0.00161	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Paclitaxel—breast cancer	0.000241	0.00161	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Capecitabine—breast cancer	0.00024	0.0016	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—EDNRB—breast cancer	0.000236	0.00399	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Thiotepa—breast cancer	0.000233	0.00155	CcSEcCtD
Azilsartan medoxomil—Rash—Vinorelbine—breast cancer	0.000232	0.00155	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Vinorelbine—breast cancer	0.000232	0.00155	CcSEcCtD
Azilsartan medoxomil—Tasosartan—CYP3A4—breast cancer	0.000231	0.0275	CrCbGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—breast cancer	0.000225	0.0038	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—breast cancer	0.000224	0.00378	CbGpPWpGaD
Azilsartan medoxomil—Rash—Thiotepa—breast cancer	0.000222	0.00148	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Thiotepa—breast cancer	0.000222	0.00148	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—ITPR1—breast cancer	0.00022	0.00372	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Vinorelbine—breast cancer	0.000219	0.00146	CcSEcCtD
Azilsartan medoxomil—Asthenia—Mitoxantrone—breast cancer	0.000218	0.00146	CcSEcCtD
Azilsartan medoxomil—Asthenia—Irinotecan—breast cancer	0.000218	0.00146	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000218	0.00145	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL1B—breast cancer	0.000215	0.00363	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP3—breast cancer	0.000214	0.00362	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2—breast cancer	0.000214	0.00362	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000214	0.00143	CcSEcCtD
Azilsartan medoxomil—Fatigue—Paclitaxel—breast cancer	0.000214	0.00143	CcSEcCtD
Azilsartan medoxomil—Asthenia—Gemcitabine—breast cancer	0.000212	0.00142	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—breast cancer	0.000211	0.00357	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—breast cancer	0.000211	0.00357	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000211	0.00141	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL20—breast cancer	0.00021	0.00355	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—breast cancer	0.00021	0.00354	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Gemcitabine—breast cancer	0.00021	0.0014	CcSEcCtD
Azilsartan medoxomil—Nausea—Thiotepa—breast cancer	0.000209	0.0014	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Irinotecan—breast cancer	0.000208	0.00139	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Mitoxantrone—breast cancer	0.000208	0.00139	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GPER1—breast cancer	0.000207	0.00349	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Docetaxel—breast cancer	0.000206	0.00138	CcSEcCtD
Azilsartan medoxomil—Pruritus—Fluorouracil—breast cancer	0.000206	0.00138	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—breast cancer	0.000205	0.00346	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Docetaxel—breast cancer	0.000204	0.00136	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—LPAR1—breast cancer	0.000203	0.00344	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Gemcitabine—breast cancer	0.000203	0.00135	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDNRB—breast cancer	0.000202	0.00342	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STARD8—breast cancer	0.000202	0.00342	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Irinotecan—breast cancer	0.000201	0.00134	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Capecitabine—breast cancer	0.0002	0.00133	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Fluorouracil—breast cancer	0.000199	0.00133	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—NMBR—breast cancer	0.000198	0.00335	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Capecitabine—breast cancer	0.000198	0.00132	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—breast cancer	0.000197	0.00333	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Epirubicin—breast cancer	0.000197	0.00131	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Epirubicin—breast cancer	0.000196	0.00131	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—breast cancer	0.000196	0.00331	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Methotrexate—breast cancer	0.000193	0.00129	CcSEcCtD
Azilsartan medoxomil—Dizziness—Fluorouracil—breast cancer	0.000193	0.00129	CcSEcCtD
Azilsartan medoxomil—Rash—Irinotecan—breast cancer	0.000192	0.00128	CcSEcCtD
Azilsartan medoxomil—Rash—Mitoxantrone—breast cancer	0.000192	0.00128	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Irinotecan—breast cancer	0.000191	0.00128	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Mitoxantrone—breast cancer	0.000191	0.00128	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GPER1—breast cancer	0.000188	0.00317	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CNR2—breast cancer	0.000187	0.00316	CbGpPWpGaD
Azilsartan medoxomil—Rash—Gemcitabine—breast cancer	0.000187	0.00125	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Gemcitabine—breast cancer	0.000187	0.00125	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTGER1—breast cancer	0.000184	0.00311	CbGpPWpGaD
Azilsartan medoxomil—Rash—Fluorouracil—breast cancer	0.000184	0.00123	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Fluorouracil—breast cancer	0.000183	0.00122	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—breast cancer	0.000182	0.00307	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Doxorubicin—breast cancer	0.000182	0.00121	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Docetaxel—breast cancer	0.000181	0.00121	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Doxorubicin—breast cancer	0.000181	0.00121	CcSEcCtD
Azilsartan medoxomil—Fatigue—Docetaxel—breast cancer	0.000181	0.00121	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Epirubicin—breast cancer	0.000181	0.00121	CcSEcCtD
Azilsartan medoxomil—Nausea—Mitoxantrone—breast cancer	0.000181	0.00121	CcSEcCtD
Azilsartan medoxomil—Nausea—Irinotecan—breast cancer	0.000181	0.00121	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—NMBR—breast cancer	0.00018	0.00304	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—breast cancer	0.00018	0.00304	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—breast cancer	0.00018	0.00304	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Paclitaxel—breast cancer	0.000178	0.00119	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—WNT1—breast cancer	0.000176	0.00297	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Gemcitabine—breast cancer	0.000176	0.00117	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Capecitabine—breast cancer	0.000176	0.00117	CcSEcCtD
Azilsartan medoxomil—Fatigue—Capecitabine—breast cancer	0.000175	0.00117	CcSEcCtD
Azilsartan medoxomil—Pruritus—Paclitaxel—breast cancer	0.000175	0.00117	CcSEcCtD
Azilsartan medoxomil—AGTR1—lymph node—breast cancer	0.000175	0.0655	CbGeAlD
Azilsartan medoxomil—Nausea—Fluorouracil—breast cancer	0.000173	0.00115	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Paclitaxel—breast cancer	0.00017	0.00113	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Doxorubicin—breast cancer	0.000167	0.00112	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—breast cancer	0.000167	0.00283	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTGER1—breast cancer	0.000167	0.00283	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—breast cancer	0.000167	0.00282	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Epirubicin—breast cancer	0.000167	0.00111	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL3—breast cancer	0.000164	0.00277	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCL27—breast cancer	0.000164	0.00277	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PDE2A—breast cancer	0.000164	0.00277	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Paclitaxel—breast cancer	0.000164	0.00109	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL2—breast cancer	0.000161	0.00272	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—AGTR2—breast cancer	0.000161	0.00272	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTHLH—breast cancer	0.000159	0.00269	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000157	0.00105	CcSEcCtD
Azilsartan medoxomil—Telmisartan—ABCB1—breast cancer	0.000157	0.0187	CrCbGaD
Azilsartan medoxomil—Rash—Paclitaxel—breast cancer	0.000156	0.00104	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Paclitaxel—breast cancer	0.000156	0.00104	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—breast cancer	0.000156	0.00263	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Doxorubicin—breast cancer	0.000154	0.00103	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDNRB—breast cancer	0.000154	0.0026	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—WNT10B—breast cancer	0.000153	0.00258	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Docetaxel—breast cancer	0.000151	0.00101	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL3—breast cancer	0.000149	0.00252	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL27—breast cancer	0.000149	0.00252	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PDE2A—breast cancer	0.000149	0.00252	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Docetaxel—breast cancer	0.000149	0.000992	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Methotrexate—breast cancer	0.000149	0.000991	CcSEcCtD
Azilsartan medoxomil—Nausea—Paclitaxel—breast cancer	0.000147	0.000983	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methotrexate—breast cancer	0.000147	0.000982	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000147	0.00098	CcSEcCtD
Azilsartan medoxomil—Asthenia—Capecitabine—breast cancer	0.000146	0.000974	CcSEcCtD
Azilsartan medoxomil—Pruritus—Capecitabine—breast cancer	0.000144	0.000961	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Docetaxel—breast cancer	0.000144	0.00096	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CALCA—breast cancer	0.00014	0.00237	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Capecitabine—breast cancer	0.000139	0.000929	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Epirubicin—breast cancer	0.000139	0.000928	CcSEcCtD
Azilsartan medoxomil—Dizziness—Docetaxel—breast cancer	0.000139	0.000928	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Epirubicin—breast cancer	0.000138	0.000919	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL12—breast cancer	0.000137	0.00231	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR4—breast cancer	0.000137	0.00231	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000136	0.000907	CcSEcCtD
Azilsartan medoxomil—Dizziness—Capecitabine—breast cancer	0.000135	0.000898	CcSEcCtD
Azilsartan medoxomil—Rash—Docetaxel—breast cancer	0.000133	0.000884	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Docetaxel—breast cancer	0.000132	0.000884	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Methotrexate—breast cancer	0.000131	0.000873	CcSEcCtD
Azilsartan medoxomil—Fatigue—Methotrexate—breast cancer	0.000131	0.000872	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Doxorubicin—breast cancer	0.000129	0.000859	CcSEcCtD
Azilsartan medoxomil—Rash—Capecitabine—breast cancer	0.000128	0.000856	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Capecitabine—breast cancer	0.000128	0.000856	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Doxorubicin—breast cancer	0.000127	0.00085	CcSEcCtD
Azilsartan medoxomil—Candesartan—ABCB1—breast cancer	0.000126	0.015	CrCbGaD
Azilsartan medoxomil—Nausea—Docetaxel—breast cancer	0.000125	0.000833	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Epirubicin—breast cancer	0.000122	0.000817	CcSEcCtD
Azilsartan medoxomil—Fatigue—Epirubicin—breast cancer	0.000122	0.000816	CcSEcCtD
Azilsartan medoxomil—Nausea—Capecitabine—breast cancer	0.000121	0.000807	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RGS2—breast cancer	0.00012	0.00203	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCL20—breast cancer	0.000119	0.002	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCDC88C—breast cancer	0.000116	0.00196	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LGR6—breast cancer	0.000116	0.00196	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—LPAR1—breast cancer	0.000115	0.00194	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000113	0.000756	CcSEcCtD
Azilsartan medoxomil—Fatigue—Doxorubicin—breast cancer	0.000113	0.000755	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—breast cancer	0.000111	0.00188	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SFRP1—breast cancer	0.000111	0.00187	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GPER1—breast cancer	0.000111	0.00187	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RGS2—breast cancer	0.000109	0.00184	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Methotrexate—breast cancer	0.000109	0.000725	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PDE4D—breast cancer	0.000109	0.00183	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL20—breast cancer	0.000108	0.00182	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—breast cancer	0.000107	0.00181	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Methotrexate—breast cancer	0.000107	0.000715	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NMBR—breast cancer	0.000106	0.0018	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CNR2—breast cancer	0.000106	0.00179	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—LPAR1—breast cancer	0.000104	0.00176	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Methotrexate—breast cancer	0.000104	0.000692	CcSEcCtD
Azilsartan medoxomil—Asthenia—Epirubicin—breast cancer	0.000102	0.000679	CcSEcCtD
Azilsartan medoxomil—Pruritus—Epirubicin—breast cancer	0.0001	0.000669	CcSEcCtD
Azilsartan medoxomil—Dizziness—Methotrexate—breast cancer	0.0001	0.000669	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HEYL—breast cancer	9.88e-05	0.00167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTGER1—breast cancer	9.88e-05	0.00167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CUL5—breast cancer	9.88e-05	0.00167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PDE4D—breast cancer	9.85e-05	0.00167	CbGpPWpGaD
Azilsartan medoxomil—Losartan—CYP3A4—breast cancer	9.77e-05	0.0116	CrCbGaD
Azilsartan medoxomil—Diarrhoea—Epirubicin—breast cancer	9.7e-05	0.000647	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CNR2—breast cancer	9.6e-05	0.00162	CbGpPWpGaD
Azilsartan medoxomil—Rash—Methotrexate—breast cancer	9.55e-05	0.000637	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methotrexate—breast cancer	9.54e-05	0.000637	CcSEcCtD
Azilsartan medoxomil—Asthenia—Doxorubicin—breast cancer	9.41e-05	0.000628	CcSEcCtD
Azilsartan medoxomil—Dizziness—Epirubicin—breast cancer	9.37e-05	0.000626	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RSPO3—breast cancer	9.29e-05	0.00157	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Doxorubicin—breast cancer	9.28e-05	0.000619	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AGTR2—breast cancer	9.09e-05	0.00154	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL2—breast cancer	9.09e-05	0.00154	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WNT10B—breast cancer	9.03e-05	0.00153	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WWOX—breast cancer	9.03e-05	0.00153	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—WNT1—breast cancer	9.03e-05	0.00153	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Methotrexate—breast cancer	9e-05	0.000601	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTHLH—breast cancer	8.99e-05	0.00152	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Doxorubicin—breast cancer	8.97e-05	0.000599	CcSEcCtD
Azilsartan medoxomil—Rash—Epirubicin—breast cancer	8.94e-05	0.000597	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Epirubicin—breast cancer	8.93e-05	0.000596	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL3—breast cancer	8.8e-05	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL27—breast cancer	8.8e-05	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDE2A—breast cancer	8.8e-05	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—INHBB—breast cancer	8.8e-05	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDNRB—breast cancer	8.71e-05	0.00147	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Doxorubicin—breast cancer	8.67e-05	0.000579	CcSEcCtD
Azilsartan medoxomil—Losartan—ALB—breast cancer	8.52e-05	0.0102	CrCbGaD
Azilsartan medoxomil—Nausea—Epirubicin—breast cancer	8.42e-05	0.000562	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BMPR2—breast cancer	8.4e-05	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DLL4—breast cancer	8.4e-05	0.00142	CbGpPWpGaD
Azilsartan medoxomil—Rash—Doxorubicin—breast cancer	8.27e-05	0.000552	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Doxorubicin—breast cancer	8.26e-05	0.000551	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AGTR2—breast cancer	8.26e-05	0.0014	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL2—breast cancer	8.26e-05	0.0014	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTHLH—breast cancer	8.17e-05	0.00138	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ABCB1—breast cancer	8.13e-05	0.00969	CrCbGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDH5—breast cancer	8.05e-05	0.00136	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CALCA—breast cancer	7.92e-05	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDNRB—breast cancer	7.91e-05	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SFRP2—breast cancer	7.9e-05	0.00133	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Doxorubicin—breast cancer	7.79e-05	0.00052	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRLR—breast cancer	7.75e-05	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL12—breast cancer	7.73e-05	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR4—breast cancer	7.73e-05	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—breast cancer	7.73e-05	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VCP—breast cancer	7.49e-05	0.00126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GLI2—breast cancer	7.49e-05	0.00126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	7.45e-05	0.00126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEPR—breast cancer	7.36e-05	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—breast cancer	7.35e-05	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CALCA—breast cancer	7.19e-05	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3CA—breast cancer	7.13e-05	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL12—breast cancer	7.02e-05	0.00119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR4—breast cancer	7.02e-05	0.00119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	6.94e-05	0.00117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ARHGDIA—breast cancer	6.85e-05	0.00116	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FST—breast cancer	6.67e-05	0.00113	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HEY2—breast cancer	6.59e-05	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RPS6KB2—breast cancer	6.51e-05	0.0011	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RGS2—breast cancer	6.44e-05	0.00109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	6.38e-05	0.00108	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL20—breast cancer	6.37e-05	0.00108	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ITPR1—breast cancer	6.27e-05	0.00106	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LPAR1—breast cancer	6.16e-05	0.00104	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TLE3—breast cancer	6.16e-05	0.00104	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HEY1—breast cancer	6.1e-05	0.00103	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DLL1—breast cancer	5.98e-05	0.00101	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	5.9e-05	0.000997	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIST1H2BC—breast cancer	5.87e-05	0.000993	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIST1H2BK—breast cancer	5.87e-05	0.000993	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRB7—breast cancer	5.82e-05	0.000984	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDE4D—breast cancer	5.82e-05	0.000984	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CSF2—breast cancer	5.79e-05	0.000979	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TAB2—breast cancer	5.72e-05	0.000967	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ITPR1—breast cancer	5.7e-05	0.000963	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CNR2—breast cancer	5.67e-05	0.000959	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—breast cancer	5.67e-05	0.000958	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MMP3—breast cancer	5.66e-05	0.000956	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	5.65e-05	0.000954	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DKK1—breast cancer	5.54e-05	0.000936	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFC—breast cancer	5.49e-05	0.000928	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAG2—breast cancer	5.41e-05	0.000915	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WNT1—breast cancer	5.33e-05	0.000901	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PLA2G4A—breast cancer	5.32e-05	0.000899	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CSF2—breast cancer	5.26e-05	0.000889	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH4—breast cancer	5.06e-05	0.000854	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GZMB—breast cancer	5.03e-05	0.000849	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL2—breast cancer	4.88e-05	0.000824	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AGTR2—breast cancer	4.88e-05	0.000824	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BMP2—breast cancer	4.82e-05	0.000815	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTHLH—breast cancer	4.82e-05	0.000815	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDNRB—breast cancer	4.67e-05	0.000789	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PGR—breast cancer	4.62e-05	0.000781	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—THBS1—breast cancer	4.6e-05	0.000778	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FLT1—breast cancer	4.39e-05	0.000742	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF3—breast cancer	4.37e-05	0.000739	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SQSTM1—breast cancer	4.37e-05	0.000739	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CG—breast cancer	4.35e-05	0.000735	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAG1—breast cancer	4.32e-05	0.00073	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH3—breast cancer	4.3e-05	0.000727	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PARP1—breast cancer	4.3e-05	0.000727	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CALCA—breast cancer	4.25e-05	0.000718	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RPS6—breast cancer	4.2e-05	0.000709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF4—breast cancer	4.16e-05	0.000704	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR4—breast cancer	4.15e-05	0.000701	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL12—breast cancer	4.15e-05	0.000701	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PAK1—breast cancer	4.07e-05	0.000688	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TCF7L2—breast cancer	4e-05	0.000676	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT2—breast cancer	3.98e-05	0.000673	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CG—breast cancer	3.95e-05	0.000668	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HSP90AA1—breast cancer	3.86e-05	0.000652	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH2—breast cancer	3.86e-05	0.000652	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CD—breast cancer	3.83e-05	0.000646	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRL—breast cancer	3.75e-05	0.000634	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADAM10—breast cancer	3.7e-05	0.000625	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STK11—breast cancer	3.7e-05	0.000625	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLG—breast cancer	3.66e-05	0.000618	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT2—breast cancer	3.62e-05	0.000611	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF10—breast cancer	3.6e-05	0.000608	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CD—breast cancer	3.47e-05	0.000587	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFA—breast cancer	3.47e-05	0.000586	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFBR2—breast cancer	3.42e-05	0.000578	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ITPR1—breast cancer	3.37e-05	0.000569	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB4—breast cancer	3.34e-05	0.000565	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP3—breast cancer	3.34e-05	0.000565	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT5A—breast cancer	3.34e-05	0.000565	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CB—breast cancer	3.33e-05	0.000563	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SMAD4—breast cancer	3.24e-05	0.000547	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1R—breast cancer	3.22e-05	0.000544	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—breast cancer	3.2e-05	0.000541	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HES1—breast cancer	3.16e-05	0.000534	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLA2G4A—breast cancer	3.14e-05	0.000531	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NCOR1—breast cancer	3.14e-05	0.000531	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF1—breast cancer	3.11e-05	0.000525	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CSF2—breast cancer	3.11e-05	0.000525	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RAF1—breast cancer	3.1e-05	0.000524	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NRG1—breast cancer	3.09e-05	0.000521	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—H2AFX—breast cancer	3.06e-05	0.000518	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2—breast cancer	3.06e-05	0.000517	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—E2F1—breast cancer	3.04e-05	0.000514	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CB—breast cancer	3.03e-05	0.000512	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SPP1—breast cancer	2.92e-05	0.000494	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—breast cancer	2.91e-05	0.000492	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB3—breast cancer	2.89e-05	0.000488	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGFR2—breast cancer	2.89e-05	0.000488	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2—breast cancer	2.78e-05	0.00047	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TERT—breast cancer	2.77e-05	0.000468	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGFR1—breast cancer	2.69e-05	0.000455	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIF1A—breast cancer	2.65e-05	0.000448	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEP—breast cancer	2.59e-05	0.000437	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CAV1—breast cancer	2.56e-05	0.000433	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KDR—breast cancer	2.53e-05	0.000428	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ESR1—breast cancer	2.47e-05	0.000417	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FN1—breast cancer	2.44e-05	0.000412	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKBIA—breast cancer	2.41e-05	0.000407	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH1—breast cancer	2.39e-05	0.000403	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APC—breast cancer	2.33e-05	0.000394	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CG—breast cancer	2.33e-05	0.000394	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KIT—breast cancer	2.33e-05	0.000394	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGF—breast cancer	2.31e-05	0.00039	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK3—breast cancer	2.24e-05	0.000378	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BRAF—breast cancer	2.19e-05	0.000371	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1—breast cancer	2.14e-05	0.000361	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT2—breast cancer	2.14e-05	0.000361	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—breast cancer	2.13e-05	0.000359	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CD—breast cancer	2.05e-05	0.000347	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CA—breast cancer	2.03e-05	0.000343	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SERPINE1—breast cancer	2.03e-05	0.000343	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KRAS—breast cancer	2.01e-05	0.000339	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOS3—breast cancer	1.94e-05	0.000327	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CA—breast cancer	1.85e-05	0.000312	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MDM2—breast cancer	1.84e-05	0.000311	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RAF1—breast cancer	1.83e-05	0.00031	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RELA—breast cancer	1.82e-05	0.000308	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB2—breast cancer	1.81e-05	0.000306	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MTOR—breast cancer	1.79e-05	0.000302	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CB—breast cancer	1.79e-05	0.000302	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—breast cancer	1.72e-05	0.00029	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRAS—breast cancer	1.71e-05	0.000289	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1B—breast cancer	1.68e-05	0.000284	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—breast cancer	1.66e-05	0.000281	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP3—breast cancer	1.65e-05	0.000278	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2—breast cancer	1.64e-05	0.000278	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—breast cancer	1.63e-05	0.000276	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCND1—breast cancer	1.6e-05	0.000271	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JUN—breast cancer	1.6e-05	0.00027	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CTNNB1—breast cancer	1.59e-05	0.000268	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—breast cancer	1.55e-05	0.000263	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1A—breast cancer	1.55e-05	0.000262	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTEN—breast cancer	1.55e-05	0.000261	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK8—breast cancer	1.51e-05	0.000255	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—breast cancer	1.51e-05	0.000255	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SRC—breast cancer	1.43e-05	0.000242	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—breast cancer	1.4e-05	0.000236	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—breast cancer	1.38e-05	0.000234	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK3—breast cancer	1.32e-05	0.000223	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—breast cancer	1.28e-05	0.000217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—breast cancer	1.28e-05	0.000217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—breast cancer	1.26e-05	0.000212	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KRAS—breast cancer	1.19e-05	0.000201	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CA—breast cancer	1.09e-05	0.000184	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—breast cancer	1.05e-05	0.000178	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRAS—breast cancer	1.01e-05	0.00017	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—breast cancer	9.66e-06	0.000163	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—breast cancer	8.91e-06	0.000151	CbGpPWpGaD
